WO2006055743A3 - Compbination growth therapy and cell therapy for treatment of acute and chronic diseases of the organs - Google Patents

Compbination growth therapy and cell therapy for treatment of acute and chronic diseases of the organs Download PDF

Info

Publication number
WO2006055743A3
WO2006055743A3 PCT/US2005/041740 US2005041740W WO2006055743A3 WO 2006055743 A3 WO2006055743 A3 WO 2006055743A3 US 2005041740 W US2005041740 W US 2005041740W WO 2006055743 A3 WO2006055743 A3 WO 2006055743A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
therapy
treated
organs
patient
Prior art date
Application number
PCT/US2005/041740
Other languages
French (fr)
Other versions
WO2006055743A2 (en
Original Assignee
Franco Wayne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/991,592 external-priority patent/US7166280B2/en
Priority claimed from US11/114,851 external-priority patent/US20050277576A1/en
Priority claimed from US11/179,245 external-priority patent/US20070111935A1/en
Application filed by Franco Wayne filed Critical Franco Wayne
Priority to EP05823219A priority Critical patent/EP1827494A4/en
Publication of WO2006055743A2 publication Critical patent/WO2006055743A2/en
Publication of WO2006055743A3 publication Critical patent/WO2006055743A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

Acute and chronic diseases of the organs are treated using a rational, multi-tier approach. A patient is pretreated with growth factor proteins or gene therapy, followed by the administration of adult stem cells or other cell therapy. The patient can be a fetus treated in utero or removed from the womb. The progress of treatment is monitored by ultrasound, MRI, CAT scan, cardiac echo, EEG, EKG, EMG or blood tests, with growth factor treatment and/or stem cell administration adjusted according to the results of the monitoring or clinical status of the patient. Organ disease is also treated by a method that comprises administration of a therapeutically effective amount of a growth factor protein by oral inhalation or intranasal therapy. Diseases affecting organs such as the brain, spinal cord, pancreas, liver, kidney, muscle, heart and upper and lower gastrointestinal tracts are treated using the present method. A device for treatment is disclosed. CPK is utilized to assess the treatment of muscle disease.
PCT/US2005/041740 2004-11-18 2005-11-17 Compbination growth therapy and cell therapy for treatment of acute and chronic diseases of the organs WO2006055743A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05823219A EP1827494A4 (en) 2004-11-18 2005-11-17 Combination growth therapy and cell therapy for treatment of acute and chronic diseases of the organs

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10/991,592 US7166280B2 (en) 2000-04-06 2004-11-18 Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
US10/991,592 2004-11-18
US11/114,851 2005-04-26
US11/114,851 US20050277576A1 (en) 2000-04-06 2005-04-26 Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US11/179,245 US20070111935A1 (en) 2000-04-06 2005-07-12 Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US11/179,245 2005-07-12

Publications (2)

Publication Number Publication Date
WO2006055743A2 WO2006055743A2 (en) 2006-05-26
WO2006055743A3 true WO2006055743A3 (en) 2008-07-17

Family

ID=36407758

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/041740 WO2006055743A2 (en) 2004-11-18 2005-11-17 Compbination growth therapy and cell therapy for treatment of acute and chronic diseases of the organs

Country Status (2)

Country Link
EP (1) EP1827494A4 (en)
WO (1) WO2006055743A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105062962B (en) * 2015-09-15 2018-09-04 广州赛莱拉干细胞科技股份有限公司 A kind of stem cell biological preparation and its preparation method and application
WO2018182612A1 (en) * 2017-03-30 2018-10-04 Progenity Inc. Methods and ingestible devices for the regio-specific release of stem cells at the site of gastrointestinal tract disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
US20020051762A1 (en) * 1998-01-23 2002-05-02 Shahin Rafii Purified populations of endothelial progenitor cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001524828A (en) * 1997-04-25 2001-12-04 コラテラル・セラピューティクス Truncated VEGF-related protein
US6759386B2 (en) * 2000-04-06 2004-07-06 Wayne P. Franco Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease
CA2412436C (en) * 2000-06-05 2013-05-21 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
JP2005501802A (en) * 2001-01-23 2005-01-20 ボストン　サイエンティフィック　コーポレイション Localized myocardial injection method for treating ischemic myocardium
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
US20040048375A1 (en) * 2001-09-30 2004-03-11 Scicotec Gmbh Application of pluripotential stem cells for body organ tissue repair and venous capillary expansion
WO2004009767A2 (en) * 2002-07-23 2004-01-29 Boston Scientific Limited Cell therapy for regeneration

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
US20020051762A1 (en) * 1998-01-23 2002-05-02 Shahin Rafii Purified populations of endothelial progenitor cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AHMED ET AL.: "The association of increased plasma MB CPK acivity and irreversible ischemic myocardial injury in the dog", CIRCULATION, vol. 54, no. 2, August 1976 (1976-08-01), pages 187 - 193, XP009127165 *
KAWAMOTO ET AL.: "Synergistic Effect of Bone Marrow Mobilization and Vascular Endothelial Growth Factor-2 Gene Therapy in Myocardial Ischemia", CIRCULATION, vol. 110, 2004, pages 1398 - 1405, XP009127171 *
RETUERTO ET AL.: "Angiogenic: pretreatment improves the efficacy of cellular cardiomyoplasty performed with fetal cardiomyocyte implantation", JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, vol. 127, no. 4, April 2004 (2004-04-01), pages 1041 - 1050, XP009127172 *
See also references of EP1827494A4 *

Also Published As

Publication number Publication date
EP1827494A4 (en) 2010-02-17
EP1827494A2 (en) 2007-09-05
WO2006055743A2 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
US20210251848A1 (en) Treatment of bleeding by non-invasive stimulation
Fenske et al. Comprehensive multilevel in vivo and in vitro analysis of heart rate fluctuations in mice by ECG telemetry and electrophysiology
CN107049232B (en) Attached heart function monitoring and/or intervention system
Hennis et al. In vivo and ex vivo electrophysiological study of the mouse heart to characterize the cardiac conduction system, including atrial and ventricular vulnerability
Stojkovic et al. Autonomic and respiratory dysfunction in Charcot–Marie–Tooth disease due to Thr124Met mutation in the myelin protein zero gene
Hernandez et al. Selected cardiopulmonary values and baroreceptor reflex in conscious green iguanas (Iguana iguana)
WO2006055743A3 (en) Compbination growth therapy and cell therapy for treatment of acute and chronic diseases of the organs
Cui et al. Electroacupuncture improved the function of myocardial ischemia involved in the hippocampus-paraventricular nucleus-sympathetic nerve pathway
CN110367970A (en) A kind of psychological condition assessment method for the women in labor stage that accuracy is high
Rogers et al. Oxidative stress in the fetal lamb brain following intermittent umbilical cord occlusion: a path analysis
Smith et al. Cardiovascular and endocrine responses to cutaneous electrical stimulation after fentanyl in the ovine fetus
Buchanan et al. Hippocampal lesions and Pavlovian cardiovascular conditioning
Booth et al. Cardiac-related rhythms in sympathetic nerve activity in preterm fetal sheep
CN1817362A (en) Chinese medicinal composition for treating heart failure and oral preparation
CN115769881B (en) Bee product double-layer tablet for improving nonspecific lumbago and preparation method thereof
Buchneva et al. Review of Problems of Registration of ECG Signals in Model Animals in Pharmacological Studies
Berlinerblau et al. Maternal arrhythmias of normal labor and delivery
RU2657840C1 (en) Method of diagnosis of myelodysplastic syndrome
CN206007248U (en) Based on the Head for diagnosis and treatment that governor vessel is diagnosed
Rajanathan et al. Hypothesis: We hypothesize that (i) our in vivo model can be utilized to investigate cardiac and vascular responses to pharmacological intervention with the α1-agonist phenylephrine, and (ii) we can study cardiovascular function during artificial pacing of the heart, modulating cardiac function without a direct vascular effect. Methods: We included 12 mice that were randomly assigned to either vehicle
CN113509287A (en) Fixing method of experimental rabbit
Natale et al. The effect of electrical stimulation on behavioral states in the fetal lamb
Sumitha A Comparative Study of Dexmedetomidine Versus Fentanyl as an Additive to 0.75% Ropivacaine in Ultrasound Guided Infraclavicular Brachial Plexus Block-A Randomized Clinical Study
CN117385022A (en) Application of IL-17A as target in preparing medicine for screening treatment or prevention of cardiac arrest
Formenti et al. Effect of Acupuncture on Diaphragm Function in Healthy Volunteers: A Pilot Clinical Study

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005823219

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005823219

Country of ref document: EP